Citi says the CSL share price can rise 23% from here

One leading broker sees a lot of upside for this biotherapeutics giant.

| More on:
Woman in celebratory fist move looking at phone

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been having a subdued week.

After charging higher following its FY 2023 results release last week, the biotherapeutics company's shares have now given back the majority of its gains.

While this is disappointing, it could prove to be a great buying opportunity for investors if Citi is on the money with its recommendation.

What is Citi saying about the CSL share price?

According to a recent note, its analysts have a buy rating and a $325 price target on the company's shares.

Based on the current CSL share price of $263.85, this implies a potential upside of just over 23% for investors over the next 12 months.

The broker is also forecasting a modest 1.6% dividend yield in FY 2024, which boosts the total return to approximately 25%.

What did the broker say?

Citi was pleased with the company's results and guidance for FY 2024. It also highlights that immunoglobulins demand is expected to remain strong and that the CSL share price would be trading in line with its 10-year average multiple if it rose to the broker's price target. It explains:

The FY23 was as pre-announced and the FY24 NPATA guidance was maintained. The new information was 1) CSL expects Ig sales to grow at HSD over the long term, driven by PID, SID and CIDP despite the incoming competition from FcRns, 2) strong Ig sales growth is expected in FY24 (mid-teens vol. + MSD pricing), 3) disclosure of timeline and magnitude of the expected Ig yield improvement, 4) ~30% decline in capex in FY24.

CSL still expects Behring GM to recover to pre-covid levels in 3-5 years, with the improvements back-end weighted (FY26-28) and multi-faceted (lower cost per litre, new products, mix shift, yield improvements). We adjust our FY24-25e NPATA per share (Core EPS) by 0%/-3%. Our new TP of $325 (from $340) implies CSL should trade on an FY26 PE of ~26x, in-line with the 10-year average. Maintain Buy.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A woman frowns and crosses her arms.
Bank Shares

40% downside! Broker values CBA shares at $80 — is the fun over?

Valuations remain the top concern among brokers.

Read more »

Two brokers analysing stocks.
Broker Notes

Citi names these 3 ASX shares to buy now

Here are the latest upgrades from Citi.

Read more »

Businessman with hands on hips looks at share price chart with the words 'buy' and 'sell '
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Broker Notes

Brokers say buy! 3 ASX shares receiving upgrades today

The experts say these ASX shares look like good buys today.

Read more »

Man with rocket wings which have flames coming out of them.
Broker Notes

These ASX stocks could rise ~30% to 45%

Bell Potter believes these stocks could generate big returns.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Close up of a sad young woman reading about declining share price on her phone.
Broker Notes

Sell this ASX 100 stock now: Goldman Sachs

Why is the broker feeling bearish about this stock? Let's find out.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Broker Notes

Where to invest $10,000 into ASX 200 shares

Analysts think these ASX shares could be top options for those funds.

Read more »